The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Spectrum Pharmaceuticals's share price is $1.03.
Spectrum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.13. Hence, Spectrum Pharmaceuticals's PS Ratio for today is 8.05.
The historical rank and industry rank for Spectrum Pharmaceuticals's PS Ratio or its related term are showing as below:
SPPI'
s PS Ratio Range Over the Past 10 Years
Min: 1.48 Med: 2.82 Max: 94.16
Current: 8.05
During the past 13 years, Spectrum Pharmaceuticals's highest PS Ratio was 94.16. The lowest was 1.48. And the median was 2.82.
SPPI's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.19
vs SPPI: 8.05
During the past 13 years, Spectrum Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 202.10% per year. The lowest was -72.90% per year. And the median was 19.70% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spectrum Pharmaceuticals's PS Ratio
For the Biotechnology subindustry, Spectrum Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectrum Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Spectrum Pharmaceuticals's PS Ratio falls into.
Spectrum Pharmaceuticals PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Spectrum Pharmaceuticals's Share Price of today is $1.03. Spectrum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Spectrum Pharmaceuticals (NAS:SPPI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Spectrum Pharmaceuticals PS Ratio Related Terms
Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPPI has been successfully added to your 